Clinical profiles, efficacy of antiarrhythmic drug therapy, and cardiovascular prognosis in patients with first detected paroxysmal atrial fibrillation

International Heart Journal

Volumn 52, Issue 1, 2011, Pages 32-38

  Komatsu, Takashi ^a   Tachibana, Hideaki ^a   Satoh, Yoshihiro ^a   Ozawa, Mahito ^a   Kunugita, Fusanori ^a   Nakamura, Motoyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiarrhythmic drug therapy; Anticoagulant therapy; Mortality; Paroxysmal atrial fibrillation; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; APRINDINE; BEPRIDIL; CIBENZOLINE; DISOPYRAMIDE; FLECAINIDE; PILSICAINIDE; WARFARIN;

AGED; ARTICLE; CARDIOVERSION; CLINICAL FEATURE; CONTROLLED STUDY; DIASTOLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART FAILURE; HEART RHYTHM; HEART VOLUME; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL HEART ATRIUM FIBRILLATION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SINUS RHYTHM; THROMBOEMBOLISM;

AGED; ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 79951468797     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.52.32     Document Type: Article

References (34)

1. Inoue H, Fujiki A, Origasa H, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol 2009; 137: 102-7.
2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-25.
3. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic feature of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-22.
4. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
5. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991; 84: 40-8.
6. Khairallah F, Ezzedine R, Ganz LI, London B, Saba S. Epidemiology and determinants of outcome of admissions for atrial fibrillation in the United States from 1996 to 2001. Am J Cardiol 2004; 94: 500-4.
7. Vidaillet H, Granada JF, Chyou PH, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002; 113: 365-70.
8. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
9. Lévy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999; 99: 3028-35.
10. Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149: 489-96.
11. Komatsu T, Nakamura S, Suzuki O, Horiuchi D, Yomogida K, Okumura K. Long-term prognosis of patients with paroxysmal atrial fibrillation depends on their response to antiarrhythmic therapy. Circ J 2004; 68: 729-33.
12. Suzuki S, Yamashita T, Ohtsuka T, et al. Prevalence and prognosis of patients with atrial fibrillation in Japan: a prospective cohort of Shinken Database 2004. Circ J 2008; 72: 914-20.
13. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: 700-52.
14. Swedberg K, Olsson LG, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 2005; 26: 1303-8.
15. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006; 47: 1997-2004.
16. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920-5.
17. Komatsu T, Tachibana H, Sato Y, Ozawa M, Nakamura M, Okumura K. Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion. Circ J 2007; 71: 46-51.
18. Kodama I, Aizawa Y, Inoue H, et al. The guideline for drug treatment of arrhythmia (JCS 2004). Circ J 2004; 68: 981-1053. (Japanese)
19. Ogawa S, Aizawa Y, Atarashi H, et al. Guidelines for pharmacotherapy of atrial fibrillation. Circ J 2008; 72: 1581-638. (Japanese)
20. Patel PJ, Keating RJ, Gersh BJ, Hodge DO, Hammill SC, Shen WK. Outcome of patients with newly diagnosed atrial fibrillation at the Mayo Clinic and residing in that area. Am J Cardiol 2004; 94: 1379-82.
21. Sopher SM, Camm AJ. Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol 1996; 77: 24A-37A. (Review)
22. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2009). Hypertens Res 2009; 32: 3-107.
23. Van Gelder IC, Crijns HJ, Tieleman RG, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996; 156: 2585-92.
24. Suttorp MJ, Kingma JH, Koomen EM, van't Hof A, Tijssen JG, Lie KI. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol 1993; 71: 710-3.
25. Kato T, Yamashita T, Sagara K, Iinuma H, Fu LT. Progressive nature of paroxysmal atrial fibrillation. Observation from a 14-year follow-up study. Circ J 2004; 68: 568-72.
26. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrilla tion (PIAF): a randomized trial. Lancet 2000; 356: 1789-94.
27. Singh SN, Tang XC, Singh BN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol 2006; 48: 721-30.
28. Ogawa S, Yamashita T, Yamazaki T, et al. Optimal treatment strategy for patients with atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-8.
29. Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008; 29: 1181-9.
30. Rivero-Ayerza M, Scholte Op Reimer WS, Lenzen M, et al. Newonset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the Euro- Heart Failure Survey. Eur Heart J 2008; 29: 1618-24.
31. Koitabashi T, Inomata T, Niwano S, et al. Paroxysmal atrial fibrillation coincident with cardiac decompensation is a predictor of poor prognosis in chronic heart failure. Circ J 2005; 69: 823-30.
32. Hamaguchi S, Yokoshiki H, Kinugawa S, et al. Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 2084-90.
33. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-7.
34. Komatsu T, Tachibana H, Sato Y, Ozawa M, Kunugida F, Nakamura M. Efficacy of antiarrhythmic drug therapy in preventing recurrence of atrial fibrillation and long-term cardiovascular prognosis in patients with asymptomatic paroxysmal atrial fibrillation. Int Heart J 2010; 51: 98-104.